

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10725965
	Filing Date		2003-12-02
	First Named Inventor	Erik Buntinx	
	Art Unit	1617	
	Examiner Name	Ramachandran, Umamaheswari	
Attorney Docket Number		29248-18	

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
/U.R./	1	5554383		1996-09-10	Dodman	
	2	5762960		1998-06-09	Dodman	
	3	5759837		1998-06-02	Kuhajda et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20030032636	A1	2003-02-13	Cremers et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS							
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	4039631	DE	A1	1992-06-17	Dr. Kerstin Bode-Greuel	Abstract
							<input checked="" type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10725965
Filing Date	2003-12-02
First Named Inventor	Erik Buntinx
Art Unit	1617
Examiner Name	Ramachandran, Umamaheswari
Attorney Docket Number	29248-18

/U.R./	2	2461248	CA		2009-09-08	Phamaneuroboost N.V.	Notice of Allowance	<input type="checkbox"/>
	3	0141701	WO	A2	2001-06-14	Cremers		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	USPTO Office Action dated 08/05/2009 in connection with related Application Serial No. 10/752,423 filed 01/06/2004, Examiner Umamaheswari Ramachandran, Art Unit 1617.	<input type="checkbox"/>
	2	USPTO Office Action dated 11/10/2009 in connection with related Application Serial No. 10/803,793 filed 03/18/2004, Examiner Benjamin J. Packard, Art Unit 1612.	<input type="checkbox"/>
	3	USPTO Office Action dated 07/21/2009 in connection with related Application Serial No. 10/984,683 filed 11/09/2004, Examiner Anna Pagonakis, Art Unit 1614.	<input type="checkbox"/>
	4	KHAN, Arif, MD et al., " Symptom Reduction and Suicide Risk in Patients Treated With Placebo in Antidepressant Clinical Trials -- An Analysis of the Food and Drug Administration Database." Arch Gen Psychiatry, Vol. 57, April 2000, pp.311-317.	<input type="checkbox"/>
	5	MONTGOMERY, Stuart A. et al., "Escitalopram versus venlafaxine XR in the treatment of depression." International Clinical Psychopharmacol, 21:297-309, 2006.	<input type="checkbox"/>
	6	MOORE, Nicholas et al., "Prospective, multicentre, randomized double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder." International Clinical Psychopharmacol, 20:131-137, 2005.	<input type="checkbox"/>
	7	NELSON, Craig J., et al., "Atypical Antipsychotic Augmentation in Major Depressive Disorder: A Meta-Analysis of Placebo-Controlled Randomized Trials." Am J Psychiatry, September 2009, 166:980-991.	<input type="checkbox"/>

/Umamaheswari Ramachandran/

07/20/2010

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10725965
Filing Date	2003-12-02
First Named Inventor	Erik Buntinx
Art Unit	1617
Examiner Name	Ramachandran, Umamaheswari
Attorney Docket Number	29248-18

/U.R./	8	PEREMANS, Kathelijne et al., "Evaluation of serotonin-2A receptor occupancy with 123 I-5-I-R91150 and single-photon emission tomography before and after low-dose pipamperone administration in the canine brain." Nuclear Medicine Communications, 29:724-729, 2008.	<input type="checkbox"/>
	9	PRINSEN, Eric P.M. et al., "The effects of antipsychotics with 5-HT <sub>2C</sub> receptor affinity in behavioral assays selective for 5-HT <sub>2C</sub> receptor antagonist properties of compounds." European Journal of Pharmacology, 2000, 388:57-67.	<input type="checkbox"/>
	10	Download from www.whocc.no/atcddd/welcome.html dated 08/20/2009, 2 pages.	<input type="checkbox"/>
	11	BUNTINX, E. et al., "Predinical and clinical evidence for the efficacy of pipamperone in augmenting the antidepressant effects of the SSRI citalopram." International Journal of Neuropsychopharmacology, volume 1, supplement 1, p. 190, July 2008.	<input type="checkbox"/>
	12	BUNTINX E et al., "Predinical and Clinical Evidence for the Efficacy of Pipamperone in Augmenting the Antidepressant Effects of the SSRI Citalopram." Poster presented at the XXVI Collegium Internationale Neuro-Psychopharmacologicum (CINP) Congress 13-17 July 2008, Munich, Germany and Summary Expected Receptor Occupancy (RO) of Pipamperone in vivo.	<input type="checkbox"/>
	13	Download, "Panic Attacks Anxiety Attacks Self-Help Anxieties OCD Social Anxiety Disorder." http://www.anxieties.com/med-intro.php, December 3, 2009, pp. 1-5.	<input type="checkbox"/>
	14	MEYERS, Urs A., "Overview of Enzymes of Drug Metabolism." Journal of Pharmacokinetics and Biopharmaceutics, Vol. 24, No. 5, 1996, pp. 449-459.	<input type="checkbox"/>
	15	OEKELEN, Dirk Van et al., "Different regulation of rat 5-HT <sub>2A</sub> and rate 5-HT <sub>2C</sub> receptors in NIH 3T3 cells upon exposure to 5-HT and pipamperone." European Journal of Pharmacology, 425, 2001, pp. 21-32	<input type="checkbox"/>
	16	WADE, Alan G. et al., "Addition of a Selective 5-HT <sub>2A/D4</sub> Antagonist Accelerates the Antidepressant Effects of Citalopram." Oasis, The Online Abstract Submission System, http://www.abstrackonline.com/submit, Control/Tracking Number: 2009-PS-1432-ACNP, 8/31/2009, pp. 1-3 & Oasis Notification System, October 5, 2009, pp. 1-3.	<input type="checkbox"/>
↓	17	USPTO Office Action dated 06/02/2009 in connection with related Application Serial No. 10/580,962 filed 05/31/2006, Examiner Sarah Pihonak, Art Unit 1617.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

/Umamaheswari Ramachandran/

07/20/2010

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10725965
Filing Date	2003-12-02
First Named Inventor	Erik Buntinx
Art Unit	1617
Examiner Name	Ramachandran, Umamaheswari
Attorney Docket Number	29248-18

**EXAMINER SIGNATURE**

Examiner Signature	/Umamaheswari Ramachandran/	Date Considered	07/20/2010
--------------------	-----------------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.